FORT LAUDERDALE, Fla., Feb. 15, 2011 /PRNewswire/ --OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a global provider of eClinical solutions and services, today announced the release of the TrialMaster® Export Utility. The TrialMaster® Export Utility is a drag and drop tool used to define export data domains, map and transform the data collection data model to the export domains, and map to industry standards such as CDISC SDTM. Exports are configured using the fully integrated validated mapping utility for repeatable exports of clinical data in formats including SAS, CDISC SDTM, and ASCII. Mapping can be performed once the data collection model has been defined, and before the final data has been collected. Once data is locked, exports will be ready to run immediately. Providing efficiencies at the data export definition provides the end users with timely exports of the data and significantly expedites the submission process.
“We are very excited for our clients with this latest release,” said Stephen Johnson, President and COO. “We continue to enhance our entire product suite to provide our customers with functionality that provides real solutions to real problems. The Export Utility was designed with input from our customer base and was nominated for the ‘2010 SCDM Data Driven Innovation Award’. It is a real game-changer that will significantly reduce the time to submission at the end of a study.”
The Export Utility was part of OmniComm’s latest release, TrialMaster ® v4.1, which also contains many other advanced enhancements. Other highlights from this release include:
- Enhanced query management system
- Redesigned reporting module with updated reports
- Updates to the SafetyLink system for management of serious adverse event data
- Integration of TrialMaster with OmniComm’s eClinical Auto-Coding solution
- Enhanced OmniConnect Application Programming Interface (API)
- Expanded Ad-Hoc Reporting functionality
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm’s growing base of satisfied customers is a direct result of the company’s commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm’s pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Safe Harbor Disclaimer Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company’s ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company’s financial results can be found in the Company’s Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
CONTACT: | |
Bev Hudson | |
OmniComm Systems, Inc. | |
954-473-1254 | |
bhudson@omnicomm.com | |
SOURCE OmniComm Systems, Inc.